IKT
Inhibikase Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$220.49M
P/E Ratio
—
EPS
$-0.44
Beta
0.97
52W High
$2.26
52W Low
$1.33
50-Day MA
$1.78
200-Day MA
$1.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Fundamentals
| Revenue (TTM) | 1 |
| Gross Profit (TTM) | $1.01M |
| EBITDA | $-48.34M |
| Operating Margin | 0.00% |
| Return on Equity | -40.20% |
| Return on Assets | -22.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.98 |
| Price-to-Book | 1.32 |
| Price-to-Sales (TTM) | 10.39 |
| EV/Revenue | 0.594 |
| EV/EBITDA | 0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $132.03M |
| Float | $86.88M |
| % Insiders | 6.42% |
| % Institutions | 93.30% |
Historical Volatility
HV 10-Day
24.07%
HV 20-Day
53.05%
HV 30-Day
49.76%
HV 60-Day
59.33%
HV Rank
0.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.88 target)
1
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026